Revenue and Expenses - Revenue for the three months ended June 30, 2024, decreased by $1.1 million (3%) to $35.021 million compared to $36.161 million in the same period of 2023, primarily due to decreased US recurring revenue from the existing client base[75]. - Direct expenses for the three months ended June 30, 2024, increased by $113,000 (1%) to $13.422 million compared to $13.309 million in 2023, with variable expenses as a percentage of revenue at 15% in 2024 and 14% in 2023[75][76]. - Selling, general, and administrative expenses decreased by $745,000 (6%) to $11.221 million in the three months ended June 30, 2024, primarily due to reduced salary and benefit costs from workforce reduction[75][77]. - Operating income for the three months ended June 30, 2024, decreased by $500,000 (5%) to $8.865 million compared to $9.365 million in 2023, reflecting the decline in revenue[75][77]. - Total other expense for the three months ended June 30, 2024, increased by $620,000, primarily due to lower interest income and higher interest expense from borrowings[78]. - Recurring Contract Value for the six months ended June 30, 2024, declined by $8.135 million (6%) to $138.434 million compared to $146.569 million in 2023, mainly due to a lack of growth in new contracts[79][83]. Cash Flow and Working Capital - Cash provided by operating activities increased by $2.236 million (13%) to $18.824 million for the six months ended June 30, 2024, compared to $16.588 million in 2023[79]. - As of June 30, 2024, the company had a working capital deficit of $28.8 million, an increase from $11.8 million on December 31, 2023, primarily due to decreases in cash and trade accounts receivable[86]. Dividends and Share Repurchase - The company paid cash dividends of $5.8 million in the six months ended June 30, 2024, with dividends of $2.9 million declared in the three months ended June 30, 2024[87]. - No shares were repurchased during the three months ended June 30, 2024, leaving 1,095,850 shares available for repurchase under the 2022 Program[98]. Debt and Borrowings - As of June 30, 2024, the outstanding balance on the Term Loan was $15.4 million, with a fixed interest rate of 5% and payable in monthly installments through May 2027[90]. - As of June 30, 2024, the outstanding balance on the Delayed Draw Term Loan was $17.9 million, with principal payments due in monthly installments of $226,190 through April 2027[92]. - The company had $9.0 million of borrowings outstanding and the availability to borrow an additional $21.0 million on the Line of Credit as of June 30, 2024[91]. - The weighted average interest rate on borrowings on the Line of Credit during the three-month and six-month periods ended June 30, 2024 was 7.67% and 7.68%, respectively[91]. - The company is required to maintain a minimum fixed charge coverage ratio of 1.10x and a cash flow leverage ratio of 3.00x or less throughout the term of the Credit Facilities[93]. - The Credit Agreement was amended in June 2023 to exclude building renovation costs from the fixed charge coverage ratio calculation, increasing the exclusion limit from $25 million to $27.5 million[96]. - The company had the availability to borrow an additional $56.0 million on the Delayed Draw Term Loan as of June 30, 2024[92]. Lease Obligations and Tax Liabilities - As of June 30, 2024, the company had fixed lease payments of $672,000 for operating leases and $12,000 for finance leases payable within 12 months[97]. - The liability for gross unrecognized tax benefits related to uncertain tax positions was $2.1 million as of June 30, 2024[97]. Credit Facilities - The Credit Facilities are secured by a first-priority lien on substantially all of the company's and its guarantors' present and future assets[94].

Financial Performance - Revenue for Q2 2024 was approximately $35 million, a decrease of 3.2% compared to $36 million in Q2 2023[2] - Earnings per diluted share were $0.26, down from $0.29 in the same quarter last year, representing a decline of 10.3%[2] - Total operating income for Q2 2024 was $8.865 million, down from $9.365 million in Q2 2023, a decrease of 5.3%[10] Contract Value - Total recurring contract value (TRCV) was approximately $138 million as of June 30, 2024[2] Acquisition - The company acquired NOBL Health for an enterprise value of approximately $6 million, with a potential earnout of up to $1 million based on future performance[6] Dividend - The company declared a quarterly cash dividend of $0.12 per share, payable on October 11, 2024[5] Debt and Liabilities - Net indebtedness was approximately $42 million as of June 30, 2024[2] - Total liabilities increased to $78.901 million from $73.482 million as of December 31, 2023[11] Stock Repurchase - The company has approximately 1.1 million shares remaining under its stock repurchase plan[4] Current Assets - Current assets decreased to $16.95 million from $24.36 million as of December 31, 2023[11]

United States' approach to nuclear energy innovation. This legislation aims to modernize the NRC's licensing and regulatory practices to be more supportive of marketplace innovation. Within one year of enactment, the NRC must submit a report to Congress detailing specific improvements to nuclear reactor and materials oversight, emphasizing efficiency through risk-informed procedures, advanced technologies, and staff training. Additionally, the ADVANCE Act requires the NRC, in collaboration with the Departme ...

National Research Corporation [NRC] Q1 2024 Earnings Conference Call May 8, 2024 11:00 AM ET Company Participants Linda Stacy - VP, Finance Mark Scudder - ELT Helen Hrdy - CCO Operator Good morning or good afternoon all, and welcome to the National Research Corporation First quarter earnings call. My name is Adam, and I'll be your operator today. [Operator instructions]. I will now hand the floor to Linda Stacy to begin. So, Linda, please go ahead when you're ready. Linda Stacy Thank you, Adam, and welcome, ...

For the quarterly period ended March 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) Delaware 47- ...

Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact:Linda A. Stacy Principal Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER RESULTS LINCOLN, Nebraska (May 7, 2024) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: "NRC continues to be strongly positioned for growth in our expanding markets. O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer inco ...

National Research Corporation (NASDAQ:NRC) Q4 2023 Earnings Conference Call February 14, 2024 11:00 AM ET Company Participants Kevin Karas – Chief Financial Officer Linda Stacy – Vice President of Finance Conference Call Participants Operator Good day, everyone, and welcome to the National Research Corporation Fourth Quarter and Year-End 2023 Earnings Call. My name is Drew, and I'll be the operator on today's call. All participants will be in a listen-only mode. There will be a Q&A. [Operator Instructions] ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State o ...

National Research Corporation (NASDAQ:NRC) Q3 2023 Results Conference Call November 8, 2023 11:00 AM ET Company Participants Kevin Karas - CFO Linda Stacy - VP, Finance Conference Call Participants Operator Hello, everyone, and welcome to the National Research Corporation Third Quarter 2023 Earnings Call. My name is Charlie and I’ll be coordinating the call today. [Operator Instructions] I’ll now hand over to our host, Kevin Karas, Chief Financial Officer, to begin. Kevin, please go ahead. Kevin Karas Thank ...